← All trials
NCT04350593
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2020
- Primary completion
- Oct 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- Apr 17, 2020
- Last posted
- Apr 17, 2020
- Enrollment
- 900
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Saint Luke's Health SystemLead sponsor
- Saint Luke's Health SystemStudy chair
- George Clinical Pty LtdCollaborator
- AstraZenecaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.